The Effect of Vasopressin Antagonists on Maternal-Separation-Induced Ultrasonic Vocalization and Stress-Hormone Level Increase during the Early Postnatal Period.

ACTH Brattleboro rat USV anxiety corticosterone maternal separation negative geotaxis pup righting reflex vasopressin antagonists

Journal

Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646

Informations de publication

Date de publication:
30 Mar 2021
Historique:
received: 02 03 2021
revised: 22 03 2021
accepted: 25 03 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 4 4 2021
Statut: epublish

Résumé

In adults, vasopressin exerts an anxiogenic effect, but less is known about the perinatal period. As a sign of distress, rat pups emit ultrasonic vocalizations when they are separated from their mothers, known as maternal separation-induced ultrasonic vocalization (MS-USV). Previously, reduced MS-USV was reported in 7-8-day-old genetically vasopressin-deficient Brattleboro rats. Here, we aimed to examine the contributing vasopressin receptor (VR) subtypes using Wistar pups. MS-USV was recorded for 10 min, 30 min after vasopressin (V) 1aR, V1bR or V2R antagonist treatment (SR49059, SSR149415, SR121463B; 3, 10 and 30 mg/kg, intraperitoneal). Sedation was studied by the righting reflex and negative geotaxis, and finally, the stress hormone levels were measured by radioimmunoassay. The vasopressin-deficient pups showed decreased MS-USV and adrenocorticotropin levels even after a saline injection, with unchanged corticosterone levels. Thirty mg/kg of V1aR-antagonist increased the corticosterone levels. All V1bR antagonist doses decreased the MS-USV and adrenocorticotropin, while 10 + 10 mg/kg of V1aR and V1bR antagonists decreased MS-USV without influencing the stress hormones. Three mg/kg of V2R antagonist enhanced MS-USV, while 30 mg/kg increased the stress hormone levels. We confirmed that vasopressin deficiency already caused anxiolytic effects in pups. V1bRs are the most important player in connection with their adrenocorticotropin (ACTH)-regulatory role, but a combination of V1aR and V1bR antagonists might be also beneficial through other mechanisms, reducing the possibility of side effects. In contrast, antagonizing the V2Rs may be stressful due to an induction of imbalance in saltwater homeostasis.

Identifiants

pubmed: 33808441
pii: brainsci11040444
doi: 10.3390/brainsci11040444
pmc: PMC8065579
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : National Research, Development and Innovation Office
ID : K 120311, K131406, PD-115730, K-129215

Références

Proc Natl Acad Sci U S A. 2006 May 16;103(20):7807-12
pubmed: 16682631
Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6370-5
pubmed: 11959912
Mol Cell Endocrinol. 1992 Aug;86(3):193-203
pubmed: 1387371
Behav Brain Res. 2016 May 15;305:18-22
pubmed: 26909846
Amino Acids. 2015 Nov;47(11):2409-18
pubmed: 26133736
Pharmacol Biochem Behav. 2005 Dec;82(4):652-7
pubmed: 16359723
Int J Dev Neurosci. 2009 Apr;27(2):175-83
pubmed: 19059472
Psychoneuroendocrinology. 1986;11(2):131-9
pubmed: 3018820
Neuroendocrinology. 1999 Feb;69(2):113-20
pubmed: 9986924
Differentiation. 1995 Oct;59(3):163-9
pubmed: 7589900
Dev Psychobiol. 1971;4(2):149-56
pubmed: 5162545
Amino Acids. 2006 Oct;31(3):241-50
pubmed: 16733617
Nihon Shinkei Seishin Yakurigaku Zasshi. 2008 Apr;28(2):93-100
pubmed: 18516988
Eur J Pharmacol. 2006 Aug 14;543(1-3):63-7
pubmed: 16843459
Eur J Pharmacol. 1993 Mar 16;233(1):101-7
pubmed: 8472738
J Clin Psychiatry. 2012 Nov;73(11):1403-11
pubmed: 23146246
J Pharmacol Exp Ther. 2000 Oct;295(1):83-90
pubmed: 10991964
Psychoneuroendocrinology. 1999 Apr;24(3):333-43
pubmed: 10101737
Physiol Rev. 2012 Oct;92(4):1813-64
pubmed: 23073632
Psychoneuroendocrinology. 1996 Feb;21(2):203-17
pubmed: 8774063
Behav Brain Res. 2008 Mar 5;187(2):371-8
pubmed: 18005969
Reprod Toxicol. 2017 Sep;72:129-135
pubmed: 28627392
Eur J Pharmacol. 2008 Apr 7;583(2-3):226-42
pubmed: 18275951
PLoS One. 2013 Sep 05;8(9):e72313
pubmed: 24039750
J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30
pubmed: 11861823
J Clin Invest. 1993 Jul;92(1):224-31
pubmed: 8392086
Eur J Pediatr. 1987 Nov;146(6):590-1
pubmed: 2962874
Br J Pharmacol. 2014 Jul;171(14):3511-25
pubmed: 24654684
Kidney Int. 2000 Oct;58(4):1613-22
pubmed: 11012895
Eur J Neurosci. 1999 Mar;11(3):997-1002
pubmed: 10103093
Psychopharmacology (Berl). 2009 Mar;202(4):711-8
pubmed: 18923820
Dev Psychobiol. 2000 Apr;36(3):186-93
pubmed: 10737864
Endocrinol Exp. 1984 Dec;18(4):209-14
pubmed: 6335081
Behav Brain Res. 2007 Mar 12;178(1):123-7
pubmed: 17227684
J Neuroendocrinol. 2003 Dec;15(12):1105-10
pubmed: 14636171
Neuroscience. 2011 Oct 27;194:62-71
pubmed: 21839808
Pharmacol Biochem Behav. 2007 Mar;86(3):431-40
pubmed: 17291571
Am J Physiol Endocrinol Metab. 2003 Nov;285(5):E1110-7
pubmed: 14534078
Cent Nerv Syst Agents Med Chem. 2012 Dec;12(4):286-303
pubmed: 22954353
Brain Res Dev Brain Res. 1991 Jan 15;58(1):13-24
pubmed: 1826642
Front Neuroendocrinol. 2017 Oct;47:154-166
pubmed: 28837830
Neuron. 2005 Aug 18;47(4):503-13
pubmed: 16102534
Horm Behav. 2007 Mar;51(3):395-405
pubmed: 17258216
J Neurosci. 1988 Nov;8(11):3967-77
pubmed: 3183709

Auteurs

Bibiána Török (B)

Institute of Experimental Medicine, 1085 Budapest, Hungary.
János Szentágothai School of Neurosciences, Semmelweis University, 1085 Budapest, Hungary.

Anna Fodor (A)

Institute of Experimental Medicine, 1085 Budapest, Hungary.
János Szentágothai School of Neurosciences, Semmelweis University, 1085 Budapest, Hungary.

Sándor Zsebők (S)

Centre for Ecological Research, Institute of Ecology and Botany, 2163 Vácrátót, Hungary.

Eszter Sipos (E)

Institute of Experimental Medicine, 1085 Budapest, Hungary.

Dóra Zelena (D)

Institute of Experimental Medicine, 1085 Budapest, Hungary.
Centre for Neuroscience, Szentágothai Research Centre, Institute of Physiology, Medical School, University of Pécs, 7622 Pécs, Hungary.

Classifications MeSH